Αρχική World News The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint Inhibitors...

The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint Inhibitors in Patients with MSI-H or dMMR Tumours

The lung immune prognostic index (LIPI) may be useful in identifying patients having tumours with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) who are likely to have no or poor response following treatment with an immune checkpoint inhibitor (ICI), including those at risk of fast progression. These  findings were presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020.

In a poster presentation, lead author Edouard Auclin of the Hôpital Européen Georges-Pompidou in Paris, France explained that MSI-H/dMMR is considered the first predictive marker for the efficacy of ICIs with tissue/site-agnostic approval. Nevertheless, according to the authors, approximately 39% of cases are refractory to ICI treatment and, to date, no additional biomarkers have been determined to identify these at-risk patients.

The investigators conducted this multicentre retrospective study to evaluate the prognostic value of the LIPI performed prior to ICI treatment in patients with MSI-H/dMMR to identify patients who may be poor responders or at risk of fast progression.

The study enrolled patients with metastatic MSI-H/dMMR tumours receiving ICIs from April 2014 to May 2019. The LIPI was calculated based on the derived neutrophil to lymphocyte ratio (dNLR) consisting of neutrophils and/or leucocytes-neutrophils >3 plus lactate dehydrogenase (LDH) greater than the upper limit of normality (ULN), as reported in the literature. The patients were categorised into one of three LIPI groups: good (0 factors), intermediate (1 factor), and poor (2 factors).

Overall survival (OS), including patients with fast progression, defined as overall survival (OS) < 3 months served as the primary endpoint while the secondary endpoint was progression-free survival (PFS).

Patients in the LIPI poor category had the poorest survival

The study identified 151 patients treated with ICIs; 59% of patients were female with a median age of 64 years. Sixty-eight percent of patients had ECOG performance status (PS) >1; 68% also had sporadic dMMR status. An ICI was administered as first or second line treatment in 59% of patients. The most frequent tumour types were gastrointestinal in 66% and gynaecological in 22% of patients.

The LIPI group classification was good in 67 (47%) patients, intermediate in 62 (43%), and poor in 14 (10%) patients.

With median follow-up of 32 months, the 24-month OS rates according to the good, intermediate, and poor risk LIPI groups were 71.1%, 54.2%, and 14.3%, respectively (p < 0.0001).

Upon analysis that adjusted for tumour site, metastatic sites, and PS, the LIPI classification of poor remained independently associated with OS (hazard ratio [HR] 3.2; 95% confidence interval [CI] 1.3-7.9, p = 0.03).

Among patients in the poor LIPI group, 16% to 35.7% of patients were fast progressors compared to 7.5% of patients with good LIPI status (p = 0.02).

The odds ratio (OR) for a fast progression event in the poor group was 6.9 [95% CI 1.7-28.6; p = 0.01].

In the patients overall, median PFS was 10.5 months (95% CI 7.1-35.1). Median PFS according to good, intermediate, and poor LIPI groups was 20.9 months (95% CI 8.4-not reached [NR]), 9.9 months (95% CI 2.8-NR), and just 2.3 months (95% CI 1.8-NR), respectively (p < 0.0001).

The-Lung-Immune-Prognostic-Index-May-Indicate-Response-to-Immune-Checkpoint-Inhibitors-in-Patients-with-MSI-H-or-dMMR-Tumours

Kaplan Meier curve for overall survival (Panel A) and progression-free survival (Panel B) according to LIPI score. Log Rank p < 0.0001 for both endpoints.

© Edouard Auclin.

Conclusions

According to the authors, the LIPI can identify patients with MSI-H and /or dMMR tumours that do not benefit from ICI treatment, particularly the fast progressors.

They recommend that the LIPI be included as stratification factor in future trials.

No external funding was reported for this study.

Reference

2P – Auclin E, Vuagnat P, Smolenschi C, et al. Lung immune prognostic index (LIPI) can identify the fast-progressor to immune checkpoints inhibitors (ICI) in microsatellite instability (MSI) or mismatch repair deficient (dMMR) tumours. ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում

«Քաղցկեղն իմ համայնքում»-ը Cancer.Net Blog շարքից է, որը ցույց է տալիս աշխարհում քաղցկեղի ազդեցությունը և թե ինչպես են մարդիկ աշխատում իրենց տարածաշրջանում քաղցկեղով մարդկանց...

Ovarian cancer screening trial did not save lives

“The effort from the start was to save lives of women with ovarian cancer. To build evidence for a screening programme that the NHS...

Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic Cervical Carcinoma

Overall survival (OS) was significantly improved with cemiplimab as compared to investigator’s choice of chemotherapy in patients with recurrent/metastatic cervical cancer and progression after...

Expressive Writing, What is It?

One of psychotherapy’s main beliefs is that putting thoughts and feelings into words may produce mental health benefits. Of course, this also applies to cancer...

Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer

May 12, 2021, by NCI Staff In triple-negative breast cancer (TNBC), tumor cells don't have estrogen receptors (ER), progesterone receptors (PR), or large amounts of...

‘Will cancer make me infertile?’ – That Cancer Conversation

For the first episode of That Cancer Conversation, we explore infertility and cancer. From teenage body worries to an intercontinental surrogacy story, we chat to...